1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CCE37AC5E89F76E48525847300271ECE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-lessons-learned-from-top-pharma-companies-about-relationships-united-states?opendocument
18
19opendocument
203.227.3.146
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Patient Advocacy

Patient Advocacy 2020: Lessons Learned from Top Pharma Companies About Relationships with Patient Advocacy Groups in the United States

ID: 5580


Features:

20 Info Graphics

2 Data Graphics

20+ Metrics

16 Narratives


Pages/Slides: 29


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient Advocacy 2020: Lessons Learned from Top Pharma Companies About Relationships with Patient Advocacy Groups in the United States”

STUDY OVERVIEW

Patient advocacy groups are an important partner for pharma in educating the United States marketplace about new therapies and treatment options. As pharma organizations seek to identify patient advocacy groups that align best with their therapeutic areas, it is critical to understand and embrace effective relationship management tactics and strategies while being compliant with regulatory guidelines.

Best Practices, LLC undertook this benchmarking research to pinpoint effective practices in patient advocacy group collaboration and relationship management in the United States. This study probes the key lessons learned and success stories of top US pharma companies in partnering with patient advocacy to shape policies, improve access, and boost patient voice.

KEY TOPICS
  • Understanding the Advocacy landscape
  • Advocacy lessons learned
  • Success stories

SAMPLE KEY FINDINGS
  • Companies must work with groups: Advocacy excellence involves diplomacy as leaders seek to bring together multiple interests. To achieve this, company employees must show respect, integrity and transparency in working with groups. It helps to define roles and expectations when establishing a working relationship.

METHODOLOGY

Best Practices, LLC engaged 48 leaders supporting patient advocacy initiatives at 43 biopharmaceutical companies in the United States through a benchmarking survey.


Industries Profiled:
Biopharmaceutical; Biotech; Communications; Pharmaceutical; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; Blue Earth Diagnostics; Boehringer Ingelheim; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Mallinckrodt; Milestone Pharmaceuticals; Natera; Novartis; Novo Nordisk; OTSUKA; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Spark Therapeutics; Theravance; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.